Published in Cancer Res on June 01, 2002
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol (2009) 1.51
TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther (2009) 1.13
Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol (2008) 1.04
Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Anticancer Res (2009) 0.98
Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther (2014) 0.92
MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis (2011) 0.92
Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells. Cancer Res (2011) 0.88
TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects. Clin Immunol (2009) 0.81
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5. Hum Gene Ther (2008) 0.81
Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther (2015) 0.80
Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells. Carcinogenesis (2008) 0.79
TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis. J Urol (2010) 0.78
Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A. Neoplasia (2012) 0.78
Tunicamycin enhances TRAIL-induced apoptosis by inhibition of cyclin D1 and the subsequent downregulation of survivin. Exp Mol Med (2009) 0.77
Aplysin sensitizes cancer cells to TRAIL by suppressing P38 MAPK/survivin pathway. Mar Drugs (2014) 0.76
Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma. FEBS J (2015) 0.75
Decreased Expression of SRSF2 Splicing Factor Inhibits Apoptotic Pathways in Renal Cancer. Int J Mol Sci (2016) 0.75
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science (2004) 11.39
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) (2012) 3.56
Yin Yang 1 is a negative regulator of p53. Cell (2004) 3.24
Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell (2007) 3.00
An IAP-IAP complex inhibits apoptosis. J Biol Chem (2004) 2.82
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest (2004) 2.59
IAP regulation of metastasis. Cancer Cell (2010) 2.47
Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci (2002) 2.40
Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest (2005) 2.32
Survivin and molecular pathogenesis of colorectal cancer. Lancet (2003) 2.25
The diagnosis and prognosis of early arthritis: rationale for new prognostic criteria. Arthritis Rheum (2002) 2.15
Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res (2003) 2.00
A p34(cdc2) survival checkpoint in cancer. Cancer Cell (2002) 1.99
Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A (2003) 1.86
Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res (2008) 1.83
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol (2005) 1.81
Regulation of microtubule stability and mitotic progression by survivin. Cancer Res (2002) 1.74
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest (2009) 1.72
Cloning and characterization of Rhodotorula glutinis thymine hydroxylase. Chem Res Toxicol (2009) 1.63
Illness beliefs predict disability in rheumatoid arthritis. J Psychosom Res (2009) 1.62
Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell (2007) 1.60
Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem (2003) 1.59
Hsp60 regulation of tumor cell apoptosis. J Biol Chem (2007) 1.57
Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell (2006) 1.57
Remission in early rheumatoid arthritis. J Rheumatol (2010) 1.55
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.54
Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res (2003) 1.54
Developmental control of apoptosis by the immunophilin aryl hydrocarbon receptor-interacting protein (AIP) involves mitochondrial import of the survivin protein. J Biol Chem (2011) 1.54
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res (2003) 1.54
Treatment of postoperative ileus after bowel surgery with low-dose intravenous erythromycin. Urology (2007) 1.52
Survival responses of human embryonic stem cells to DNA damage. J Cell Physiol (2009) 1.51
A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res (2008) 1.46
Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis. Clin Transplant (2012) 1.44
Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res (2006) 1.44
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One (2009) 1.44
Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med (2002) 1.42
Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: impact on patient outcomes and costs. Urology (2005) 1.41
Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest (2011) 1.41
Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. J Rheumatol (2011) 1.40
Laparoscopic management of bilateral page kidneys. Urology (2007) 1.39
Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem (2003) 1.37
Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. BMJ (2002) 1.37
Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle (2009) 1.36
Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun (2013) 1.29
Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest (2013) 1.28
IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J Immunol (2009) 1.28
Cold atmospheric plasma for the ablative treatment of neuroblastoma. J Pediatr Surg (2013) 1.27
Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem (2005) 1.27
Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol (2009) 1.26
Survivin is released from cancer cells via exosomes. Apoptosis (2011) 1.25
Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res (2008) 1.24
Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One (2012) 1.23
Huntingtin associates with acidic phospholipids at the plasma membrane. J Biol Chem (2005) 1.22
Infection of human urethral epithelium with Neisseria gonorrhoeae elicits an upregulation of host anti-apoptotic factors and protects cells from staurosporine-induced apoptosis. Cell Microbiol (2003) 1.21
Fibromyalgic rheumatoid arthritis and disease assessment. Rheumatology (Oxford) (2010) 1.21
Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res (2010) 1.19
Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol (2011) 1.19
A survivin gene signature predicts aggressive tumor behavior. Cancer Res (2005) 1.17
Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res (2005) 1.17
Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell (2012) 1.17
Use of bipolar energy for transurethral resection of bladder tumors: pathologic considerations. J Endourol (2004) 1.17
The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol (2005) 1.16
African American living-kidney donors should be screened for APOL1 risk alleles. Transplantation (2011) 1.15
Donation after cardiac death: the University of Wisconsin experience. Ann Transplant (2004) 1.14
A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.13
Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother (2007) 1.13
Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res (2006) 1.13
Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res (2006) 1.12
Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett (2010) 1.12
Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res (2009) 1.11
Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer (2009) 1.11
Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome? BJU Int (2006) 1.09
Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways. Cancer Res (2006) 1.07
Setting goals, solving problems, and seeking social support: developing adolescents' abilities through a life skills program. Adolescence (2007) 1.07
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst (2006) 1.06
Gonococcal porin IB activates NF-kappaB in human urethral epithelium and increases the expression of host antiapoptotic factors. Infect Immun (2004) 1.06
Experience with alternate sources of venous inflow in the meso-Rex bypass operation: the coronary and splenic veins. J Pediatr Surg (2007) 1.05
Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J Biol Chem (2006) 1.05
The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clin Rheumatol (2011) 1.03
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. Clin Cancer Res (2004) 1.03
Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem (2006) 1.03
CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res (2003) 1.03
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01
Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res (2010) 1.01
Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein. Arterioscler Thromb Vasc Biol (2005) 1.01
Quality of life and the outcome of established rheumatoid arthritis. Best Pract Res Clin Rheumatol (2011) 1.00
Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res (2003) 1.00
The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int (2008) 1.00
H-type congenital tracheoesophageal fistula: University Of Iowa experience 1985 to 2005. Ann Otol Rhinol Laryngol (2007) 1.00
Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. Clin Cancer Res (2006) 0.99
Historical evolution of transurethral resection at the University of Iowa: Alcock and Flocks. J Urol (2008) 0.99
Postnatal expansion of the pancreatic beta-cell mass is dependent on survivin. Diabetes (2008) 0.99